Holen Sie sich die Stockscreener-App
1.11
4.72%
0.05
Handel nachbörslich:
1.14
0.03
+2.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.06
Offen:
$1.06
24-Stunden-Volumen:
2.31M
Relative Volume:
0.58
Marktkapitalisierung:
$403.37M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.3875
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-3.48%
1M Leistung:
+2.78%
6M Leistung:
+49.74%
1J Leistung:
-35.84%
1-Tages-Spanne:
$1.05
$1.12
1-Wochen-Bereich:
$1.02
$1.27
52-Wochen-Spanne:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.11 | 377.93M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyFree Technical Signal Summary - newsyoung.net
Is Lexicon Pharmaceuticals Inc. stock entering bullish territoryDay Trading Setup and Momentum Analysis - Newser
Has Lexicon Pharmaceuticals Inc. formed a bullish divergenceShort-Term Market Movement Forecast Report - Newser
Published on: 2025-08-11 05:26:29 - Newser
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceAlpha Stock Picks with Chart Confirmation - Newser
Leerink Partnrs Brokers Increase Earnings Estimates for LXRX - Defense World
Will breakout in Lexicon Pharmaceuticals Inc. lead to full recoveryMarket Timing Strategy with Technical Filters - Newser
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.Free Conservative Long Term Growth Plans - Newser
How high can Lexicon Pharmaceuticals Inc. stock price go in 20252-Day Signal Watch with Forecast Outcome - Newser
Trendline Breach Raises Concern for Lexicon Pharmaceuticals Inc. InvestorsWeekly Return Pick Forecast Reports Show Trend - metal.it
Lexicon Pharmaceuticals Inc. Stock Approaches Key Moving AverageTechnical Stock Breakout Predictions Signal Entry Points - beatles.ru
Lexicon Pharmaceuticals Advances Sotagliflozin Study for Hypertrophic Cardiomyopathy Treatment - AInvest
What momentum shifts mean for Lexicon Pharmaceuticals Inc.Predictive Model for Intraday Swing Forecast - Newser
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Community Picked Stocks with Trade Insights - Newser
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy - TipRanks
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges - TipRanks
Citigroup Raises Lexicon Pharmaceuticals PT to $1.9, Maintains Buy Rating - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $1.9 - 富途牛牛
Lexicon: Q2 Earnings Snapshot - New Haven Register
Lexicon Pharmaceuticals 2025 Q2 Earnings Remarkable Turnaround with 106.1% Net Income Increase - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Average Target Price from Analysts - Defense World
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 By Investing.com - Investing.com Nigeria
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 - Investing.com
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance - AInvest
Lexicon Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Reports Surprising Q2 Earnings and RevenueNews and Statistics - IndexBox
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates - sharewise.com
Lexicon Pharmaceuticals Q2 product revenue USD 1.322 million - MarketScreener
LEXICON PHARMACEUTICALS Earnings Results: $LXRX Reports Quarterly Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS - GuruFocus
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Q2 EPS Surpasses Expectations, Revenue Jumps 1649.7% YoY - AInvest
Lexicon Pharmaceuticals reports Q2 results, Phase 2b PROGRESS study results, and Q3 enrollment target. - AInvest
Evaluating Lexicon Pharmaceuticals' Q2 2025 Earnings and Institutional Investor Sentiment: A Path to Value Creation Amid Mixed Analyst Ratings - AInvest
Published on: 2025-08-04 19:08:28 - metal.it
Lexicon Pharmaceuticals Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
Published on: 2025-08-04 02:57:12 - Jammu Links News
What is the risk reward ratio of investing in Lexicon Pharmaceuticals Inc. stockMarket-beating performance - Jammu Links News
What are Lexicon Pharmaceuticals Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
What are analysts’ price targets for Lexicon Pharmaceuticals Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockConsistent triple returns - Jammu Links News
Does Lexicon Pharmaceuticals Inc. stock perform well during market downturnsGet timely alerts on market movers - Jammu Links News
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Tap into rapid wealth building techniques - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - Jammu Links News
How does Lexicon Pharmaceuticals Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
What drives Lexicon Pharmaceuticals Inc. stock priceSky-high profits - Jammu Links News
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):